Lexeo Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006
Industry News
News|Jun 30 2021
LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package to Support Cardiac Friedreich’s Ataxia Gene Therapy Program (LX2006)